|1.||Miller, S D: 1 article (06/2015)|
|2.||Luo, X: 1 article (06/2015)|
|3.||Galvin, J P: 1 article (06/2015)|
|4.||McCarthy, D P: 1 article (06/2015)|
|5.||Bryant, J: 1 article (06/2015)|
|6.||Pliszka, Barbara: 1 article (02/2002)|
|7.||Karczewska, Emilia: 1 article (02/2002)|
02/11/2002 - "It has been previously shown that in the M-MgADP-P(i) state, where the myosin head adopts a pre-power stroke conformation, treatment of trypsin-split subfragment 1 of skeletal muscle myosin with 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) results in cross-linking of the C-terminal fragment of the heavy chain of S1 -- most probably its converter region -- to the N-terminal S1 heavy-chain fragment, generating a product of 44 kDa [Biochim. "
06/01/2015 - "The use of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (ECDI)-treated, autoantigen-coupled syngeneic leukocytes has been developed as a specific immunotherapy in preclinical models of autoimmunity and is currently in a phase II clinical trial for the treatment of multiple sclerosis. "
|3.||Adenosine Diphosphate (ADP)